Korro Bio Inc
KRRO33.220USD
+2.840+9.35%
收盘 09/18, 16:00（美东）报价延迟15分钟
311.96M总市值
亏损市盈率 TTM
关于 Korro Bio Inc 公司
Korro Bio, Inc. 是一家生物制药公司。该公司发现、开发和商业化基于编辑核糖核酸 (RNA) 的基因药物，从而能够治疗罕见和高度流行的疾病。该公司正在生成一系列差异化项目，旨在利用人体天然的 RNA 编辑过程来实现精确但短暂的单碱基编辑。通过编辑 RNA 而不是 DNA，该公司正在扩大基因药物的覆盖范围。其寡核苷酸促进的 RNA 编辑 (OPERA) 是 RNA 编辑的基础平台，旨在通过提供可以靶向特定 RNA 序列的寡核苷酸向导来编辑体内 RNA。该公司的首个开发候选药物 KRRO-110 正在开发中，作为 Alpha-1 抗胰蛋白酶缺乏症 (AATD) 的潜在治疗方法，具有改变疾病并提供差异化治疗选择的潜力。
公司简介
公司代码KRRO
公司名称Korro Bio Inc
上市日期Oct 03, 2019
CEODr. Ram Aiyar, Ph.D.
员工数量104
证券类型Ordinary Share
年结日Oct 03
公司地址One Kendall Square. Building 600-700
城市CAMBRIDGE
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编02139
电话16174681999
网址https://www.korrobio.com/
公司代码KRRO
上市日期Oct 03, 2019
CEODr. Ram Aiyar, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Nessan Bermingham, Ph.D.
Dr. Nessan Bermingham, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
35.11K
--
Mr. Jeffrey (Jeff) Cerio, Pharm.D.
Mr. Jeffrey (Jeff) Cerio, Pharm.D.
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
--
--
Mr. Oliver Dolan
Mr. Oliver Dolan
Principal Accounting Officer
Principal Accounting Officer
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
--
--
Mr. Venkat Krishnamurthy, Ph.D.
Mr. Venkat Krishnamurthy, Ph.D.
Senior Vice President - Platform
Senior Vice President - Platform
--
--
Ms. Stephanie Engels
Ms. Stephanie Engels
Senior Vice President - People and Culture
Senior Vice President - People and Culture
--
--
Dr. Rachel Meyers, Ph.D.
Dr. Rachel Meyers, Ph.D.
Independent Director
Independent Director
--
--
Mr. Vineet Agarwal
Mr. Vineet Agarwal
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Katharine (Kate) Knobil, M.D.
Dr. Katharine (Kate) Knobil, M.D.
Independent Director
Independent Director
--
--
Mr. Todd Chappell
Mr. Todd Chappell
Chief Operating Officer
Chief Operating Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Nessan Bermingham, Ph.D.
Dr. Nessan Bermingham, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
35.11K
--
Mr. Jeffrey (Jeff) Cerio, Pharm.D.
Mr. Jeffrey (Jeff) Cerio, Pharm.D.
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
--
--
Mr. Oliver Dolan
Mr. Oliver Dolan
Principal Accounting Officer
Principal Accounting Officer
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
--
--
Mr. Venkat Krishnamurthy, Ph.D.
Mr. Venkat Krishnamurthy, Ph.D.
Senior Vice President - Platform
Senior Vice President - Platform
--
--
Ms. Stephanie Engels
Ms. Stephanie Engels
Senior Vice President - People and Culture
Senior Vice President - People and Culture
--
--
收入明细
FY2025Q1
FY2024
暂无数据
地区USD
名称
营收
占比
United States
2.55M
0.00%
业务
地区
暂无数据
股东统计
更新时间: 8月16日 周六
更新时间: 8月16日 周六
持股股东
股东类型
持股股东
持股股东
占比
Atlas Venture
12.11%
New Enterprise Associates (NEA)
11.62%
Fidelity Management & Research Company LLC
6.81%
Driehaus Capital Management, LLC
6.19%
Platanus Investment LLC
5.75%
其他
57.53%
持股股东
持股股东
占比
Atlas Venture
12.11%
New Enterprise Associates (NEA)
11.62%
Fidelity Management & Research Company LLC
6.81%
Driehaus Capital Management, LLC
6.19%
Platanus Investment LLC
5.75%
其他
57.53%
股东类型
持股股东
占比
Investment Advisor
30.32%
Hedge Fund
27.36%
Venture Capital
23.72%
Investment Advisor/Hedge Fund
13.95%
Corporation
5.75%
Research Firm
1.37%
Individual Investor
0.42%
Private Equity
0.34%
Pension Fund
0.12%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
186
10.38M
110.55%
-200.85K
2025Q1
189
10.53M
112.24%
-76.97K
2024Q4
194
10.26M
109.50%
+485.90K
2024Q3
177
9.16M
98.29%
-245.98K
2024Q2
167
9.06M
97.57%
+507.87K
2024Q1
179
7.52M
93.89%
+737.20K
2023Q4
198
7.18M
91.01%
+1.51M
2023Q3
223
264.10K
35.84%
-47.15K
2023Q2
235
150.53K
21.10%
-156.09K
2023Q1
266
144.14K
20.36%
-179.94K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Atlas Venture
1.14M
12.11%
--
--
Apr 15, 2025
New Enterprise Associates (NEA)
1.09M
11.62%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
643.27K
6.85%
+1.53K
+0.24%
Mar 31, 2025
Driehaus Capital Management, LLC
582.45K
6.2%
+87.54K
+17.69%
Mar 31, 2025
Platanus Investment LLC
540.16K
5.75%
--
--
Apr 15, 2025
Point72 Asset Management, L.P.
520.89K
5.55%
+26.89K
+5.44%
Mar 31, 2025
Cormorant Asset Management, LP
380.30K
4.05%
+380.30K
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
407.81K
4.34%
-7.23K
-1.74%
Mar 31, 2025
Invus Public Equities Advisors, LLC
418.83K
4.46%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
381.80K
4.07%
-5.99K
-1.55%
Mar 31, 2025
查看更多
持股ETF
更新时间: 9月2日 周二
更新时间: 9月2日 周二
机构名称
占比
iShares Micro-Cap ETF
0.02%
Avantis US Small Cap Equity ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
ProShares UltraPro Russell2000
0%
SPDR Portfolio MSCI Global Stock Market ETF
0%
ProShares Hedge Replication ETF
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
iShares Russell 2000 Growth ETF
0%
iShares Health Innovation Active ETF
0%
iShares Russell 3000 ETF
0%
查看更多
iShares Micro-Cap ETF
占比0.02%
Avantis US Small Cap Equity ETF
占比0.01%
iShares Russell 2000 Value ETF
占比0.01%
ProShares UltraPro Russell2000
占比0%
SPDR Portfolio MSCI Global Stock Market ETF
占比0%
ProShares Hedge Replication ETF
占比0%
Invesco Dorsey Wright SmallCap Momentum ETF
占比0%
iShares Russell 2000 Growth ETF
占比0%
iShares Health Innovation Active ETF
占比0%
iShares Russell 3000 ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
公告日期
类型
比率
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
